Sovaldi may be taken with or without food, but alcohol can worsen liver disease. Patients with chronic hepatitis C should discuss alcohol consumption with their healthcare provider to determine a safe level.
Take the missed tablet as soon as you remember unless the next scheduled dose is within a few hours. Do not double up on doses; instead, continue with the regular daily schedule.
When traveling, keep Sovaldi in its original packaging, protected from heat and moisture. Carry a copy of the prescription and a letter from your clinician describing the medication, as some countries may require documentation for antiviral drugs.
Sovaldi’s active ingredient, sofosbuvir, specifically inhibits the NS5B polymerase, a mechanism not shared by all hepatitis C drugs. This enables high cure rates when combined with other agents, often allowing shorter treatment durations.
Sovaldi tablets are round, film-coated, and white to off-white in colour. Each tablet contains 400 mg of sofosbuvir and includes inactive ingredients such as lactose and magnesium stearate.
For patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m²), no dose adjustment is required. However, severe renal impairment (eGFR < 30) is a contraindication, and alternative regimens should be considered.
Yes, for certain HCV genotypes (e.g., genotype 2 or 3), Sovaldi is often prescribed together with ribavirin to increase cure rates. The combination and treatment length are determined by the prescriber based on genotype and disease severity.
Regular blood tests are needed to assess HCV RNA levels, liver enzymes, and renal function. A final HCV RNA test 12 weeks after treatment confirms whether a sustained virologic response has been achieved.
Do not flush or throw Sovaldi tablets into household waste. Return unused or expired medication to a pharmacy collection point or follow local waste-disposal guidelines for pharmaceuticals.
Sovaldi may be prescribed on the NHS for eligible patients with chronic hepatitis C, subject to clinical criteria and local commissioning policies. Patients should discuss eligibility and potential costs with their prescriber.
Sovaldi is a brand-name antiviral medication that contains the active ingredient sofosbuvir. It is supplied as a 400 mg oral tablet (pill) and is classified within the antiviral drug group. In the United Kingdom, Sovaldi is a prescription-only medicine regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Sofosbuvir works by targeting the hepatitis C virus (HCV) and is used as part of combination regimens to treat chronic HCV infection.
Sofosbuvir is a direct-acting antiviral (DAA) that inhibits the HCV NS5B RNA-dependent RNA polymerase, an enzyme essential for viral replication. By blocking this polymerase, the drug prevents the virus from copying its genetic material, thereby reducing viral load. The inhibition is potent and selective, leading to a rapid decline in circulating HCV RNA. Sofosbuvir is well absorbed after oral administration, reaches peak plasma concentrations within 0.5-2 hours, and is metabolised intracellularly to its active triphosphate form, which exerts the antiviral effect. The drug’s half-life supports once-daily dosing.
Sovaldi is approved in the UK for the treatment of chronic hepatitis C infection caused by genotypes 1, 2, 3, 4, 5 and 6 when used in combination with other antiviral agents such as ribavirin, ledipasvir, or velpatasvir. The typical therapeutic goal is a sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after completing therapy, which is considered a cure.
Therapy duration varies by regimen but most patients receive a 12-week course.
Current peer-reviewed evidence does not support routine off-label use of Sofosbuvir for infections other than hepatitis C. Small experimental studies have explored its activity against other flaviviruses, but these investigations remain pre-clinical. Consequently, no off-label indications are recommended at this time.
These effects are generally mild and tend to resolve without intervention.
Missed dose: Take the missed tablet as soon as remembered unless it is near the time of the next scheduled dose; do not double the dose.
Overdose: Symptoms may include nausea, vomiting, and dizziness. Seek emergency medical care; supportive measures are the mainstay of treatment.
Discontinuation: No tapering is required. If therapy is stopped prematurely, resistance may develop; patients should discuss alternative plans with their prescriber.
This article provides educational information about Sovaldi and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
